Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (currently amended) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a ~~CCR-2~~ chemokine receptor-2 antagonist.

2. (previously presented) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula:



wherein:

X is selected from the group consisting of:

-O-, -NR^{20}-, -S-, -SO-, -SO_2-, and -$CR^{21}R^{22}$-, -NSO_2R^{20}-, -$NCOR^{20}$-, -NCO_2R^{20}-, -$CR^{21}CO_2R^{20}$-, -$CR^{21}OCOR^{20}$-, -CO-,

where R^{20} is selected from: hydrogen, C_{1-6} alkyl, benzyl, phenyl, C_{3-6} cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C_{1-3}alkyl, C_{1-3}alkoxy, -CO_2H, -CO_2-C_{1-6} alkyl, and trifluoromethyl,

where R^{21} and R^{22} are independently selected from: hydrogen, hydroxy, C_{1-6} alkyl, -O-C_{1-6}alkyl, benzyl, phenyl, C_{3-6} cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C_{1-3}alkyl, C_{1-3}alkoxy, -CO_2H, -CO_2-C_{1-6} alkyl, and trifluoromethyl;

R^1 is selected from:

-C_{1-6}alkyl, -C_{0-6}alkyl-O-C_{1-6}alkyl-, -C_{0-6}alkyl-S-C_{1-6}alkyl-, -(C_{0-6}alkyl)-(C_{3-7}cycloalkyl)-(C_{0-6}alkyl), hydroxy, -CO_2R^{20}, heterocycle, -CN, -$NR^{20}R^{26}$-, -NSO_2R^{20}-, -$NCOR^{20}$-, -NCO_2R^{20}-, -$NCOR^{20}$-, -$CR^{21}CO_2R^{20}$-, -$CR^{21}OCOR^{20}$-, phenyl and pyridyl,

where R^{26} is selected from: hydrogen, C_{1-6} alkyl, benzyl, phenyl, C_{3-6} cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C_{1-3}alkyl, C_{1-3}alkoxy, -CO_2H, -CO_2-C_{1-6} alkyl, and trifluoromethyl

where the alkyl and the cycloalkyl are unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl,
(f) C_{1-3}alkyl,
(g) -O-C_{1-3}alkyl,
(h) -CO_2R^{20},
(i) -SO_2R^{20},
(j) -$NHCOCH_3$,
(k) -$NHSO_2CH_3$,
(l) -heterocycle,
(m) =O,
(n) -CN,

and where the phenyl and pyridyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C_{1-3}alkyl, C_{1-3}alkoxy and trifluoromethyl;

R^2 is selected from:

(a) hydrogen,
(b) hydroxy,
(c) halo,
(d) C_{1-3}alkyl, where the alkyl is unsubstituted or substituted with 1-6 substituents independently selected from: fluoro, and hydroxy,
(e) -$NR^{20}R^{26}$,
(f) -CO_2R^{20},

(g) $-CONR^{20}R^{26}$,
(h) $-NR^{20}COR^{21}$,
(i) $-OCONR^{20}R^{26}$,
(j) $-NR^{20}CONR^{20}R^{26}$,
(k) -heterocycle,
(l) -CN,
(m) $-NR^{20}-SO_2-NR^{20}R^{26}$,
(n) $-NR^{20}-SO_2-R^{26}$,
(o) $-SO_2-NR^{20}R^{26}$, and
(p) =O, where R^2 is connected to the ring via a double bond;

R^3 is oxygen or is absent;

R^4 is selected from:

(a) hydrogen,
(b) C_{1-6}alkyl,
(c) trifluoromethyl,
(d) trifluoromethoxy,
(e) chloro,
(f) fluoro,
(g) bromo, and
(h) phenyl;

R^5 is selected from:

(a) C_{1-6}alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro and optionally substituted with hydroxyl,
(b) $-O-C_{1-6}$alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
(c) $-CO-C_{1-6}$alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
(d) $-S-C_{1-6}$alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
(e) -pyridyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: halo, trifluoromethyl, C_{1-4}alkyl, and CO_2R^{20},
(f) fluoro,

(g) chloro,
(h) bromo,
(i) -C_{4-6}cycloalkyl,
(j) -O-C_{4-6}cycloalkyl,
(k) phenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of : halo, trifluoromethyl, C_{1-4}alkyl, and CO_2R^{20},
(l) -O-phenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of : halo, trifluoromethyl, C_{1-4}alkyl, and CO_2R^{20},
(m) -C_{3-6}cycloalkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
(n) -O-C_{3-6}cycloalkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
(o) -heterocycle,
(p) -CN, and
(q) -CO_2R^{20};

R^6 is selected from:

(a) hydrogen,
(b) C_{1-6}alkyl, and
(c) trifluoromethyl
(d) fluoro
(e) chloro, and
(f) bromo;

R^7 is selected from:

(a) hydrogen, and
(b) C_{1-6}alkyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, -CO_2H, -CO_2C_{1-6}alkyl, and –O-C_{1-3}alkyl;

R^8 is selected from:

(a) hydrogen,
(b) C_{1-6}alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C_{1-3}alkoxy, hydroxy, -CO_2R^{20},

(c) fluoro,
(d) -O-C_{1-3}alkyl, where alkyl may be unsubstituted or substituted with 1-3 fluoro, and
(e) C_{3-6} cycloalkyl,
(f) -O-C_{3-6}cycloalkyl,
(g) hydroxy,
(h) -CO_2R^{20},
(i) -$OCOR^{20}$,
or R^7 and R^8 may be joined together via a C_{2-4}alkyl or a C_{0-2}alkyl-O-C_{1-3}alkyl chain to form a 5-7 membered ring;

R^9 is selected from:

(a) hydrogen,
(b) C_{1-6}alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C_{1-3}alkoxy, hydroxy, -CO_2R^{20},
(c) CO_2R^{20},
(d) hydroxy, and
(e) -O-C_{1-6}alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C_{1-3}alkoxy, hydroxy, -CO_2R^{20},
or R^8 and R^9 may be joined together by a C_{1-4}alkyl chain or a C_{0-3}alkyl-O-C_{0-3}alkyl chain to form a 3-6 membered ring;

R^{10} is selected from:

(a) hydrogen, and
(b) C_{1-6}alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
(c) fluoro,
(d) -O-C_{3-6}cycloalkyl, and
(e) -O-C_{1-3}alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
or R^8 and R^{10} may be joined together by a C_{2-3}alkyl chain to form a 5-6 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substiuents are independently selected from: halo, hydroxy, -CO_2R^{20}, C_{1-3}alkyl, and C_{1-3}alkoxy,

or R^8 and R^{10} may be joined together by a C_{1-2}alkyl-O-C_{1-2}alkyl chain to form a 6-8 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substiuents are independently selected from: halo, hydroxy, $-CO_2R^{20}$, C_{1-3}alkyl, and
C_{1-3}alkoxy,
or R^8 and R^{10} may be joined together by a –O-C_{1-2}alkyl-O-chain to form a 6-7 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substiuents are independently selected from: halo, hydroxy, $-CO_2R^{20}$, C_{1-3}alkyl, and
C_{1-3}alkoxy;

n is selected from 0, 1 and 2;
the dashed line represents the optional presence of a second bond to form a double bond;
and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

3. (previously presented) The method according to claim 2, wherein X is oxygen.

4. (previously presented) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula:



5. (New) The method of Claim 2, wherein R^1 is isopropyl, R^2 is hydrogen, R^3 is absent, R^4 is hydrogen, R^5 is $-CF_3$, R^6 is hydrogen, R^7 is hydrogen, R^8 is $-OCH_3$, R^9 is hydrogen, X is oxygen, R^{10} is hydrogen, n is 1, and the dashed line is absent, so that the 5-membered ring has no double bonds.